Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
2018 · New England Journal of Medicine · 3,376 citations
https://doi.org/10.1056/nejmoa1801174
G
Gregory G. Schwartz
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
372
Papers
22.6K
Citations
65
h-index
165
i10-index
Gregory G. Schwartz is an academic researcher from Northwestern University. The author has contributed to research in topics: Lipoproteins and Cardiovascular Health & Health Systems, Economic Evaluations, Quality of Life & Antiplatelet Therapy and Cardiovascular Diseases. The author has an h-index of 65, co-authored 317 publications.
ORCID: 0000-0003-2954-0695Papers by this author
worksEffect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
2020 · Journal of the American College of Cardiology · 545 citations
https://doi.org/10.1016/j.jacc.2019.10.057
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
2018 · The Lancet · 528 citations
https://doi.org/10.1016/s0140-6736(18)31652-0
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
2014 · American Heart Journal · 409 citations
https://doi.org/10.1016/j.ahj.2014.07.028
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome
2019 · Journal of the American College of Cardiology · 225 citations
https://doi.org/10.1016/j.jacc.2019.03.013
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events
2018 · Journal of the American College of Cardiology · 170 citations
https://doi.org/10.1016/j.jacc.2018.10.039
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat